肺动脉高压急性血管反应阳性:现代管理时代的治疗后果、模式与结局
该回顾性多中心研究纳入1999至2018年15家肺高压中心诊断的PAH患者,评估急性血管反应阳性者接受钙通道阻滞剂(CCB)治疗的长期反应与结局。1904例接受急性血管反应测试,162例符合阳性标准并起始CCB治疗;12个月时54.3%为CCB长期反应者,其5年生存率98.5%显著高于非反应者的73.0%。
要点
- 急性血管反应阳性患者中仅54.3%在12个月时达到CCB长期反应。
- CCB长期反应者5年生存率98.5%,非反应者为73.0%。
- 早期随访中低风险状态、NT-proBNP及肺动脉顺应性可预测长期反应。
核心结论
- 血管反应阳性人群存在异质性,相当一部分患者未能对CCB维持满意临床反应。
- 早期随访综合再评估十分必要,肺动脉顺应性可能有助于识别长期反应者。
研究设计与样本
- 多中心回顾性研究,纳入1999年1月至2018年12月15家肺高压中心诊断的PAH患者。
- 3702例因PAH诊断行右心导管检查,其中2051例为特发性、遗传性或药物诱导性PAH,1904例(92.8%)接受急性血管反应测试。
- 162例符合急性血管反应标准并起始CCB单药(n=123)或联合其他PAH治疗(n=39),随访至多5年。
主要发现
- 中位随访60.0个月(IQR 30.8-60.0),总生存率86.7%。
- 12个月时53.2%维持CCB单药,14.7%维持初始CCB联合其他初始PAH治疗,其余患者停用CCB和/或加用PAH治疗。
- CCB长期反应者占54.3%;长期反应者5年生存率98.5%,非反应者73.0%。
- 除既定血管扩张反应标准外,急性血管反应测试时的肺动脉顺应性、早期随访的低风险状态和NT-proBNP水平与长期反应相关并预测生存。
关键数值与推荐
- 急性血管反应阳性定义:平均肺动脉压下降≥10 mm Hg至<40 mm Hg,且心输出量不下降。
- CCB长期反应定义:起始CCB治疗12个月时存活、初始CCB治疗未改变(±其他初始PAH治疗),且WHO功能分级I/II和/或ESC/ERS低风险状态。
临床怎么用
- 对急性血管反应阳性患者启动CCB后应在早期随访中全面再评估,包括功能分级、风险状态和NT-proBNP。
- 肺动脉顺应性可在急性血管反应测试时辅助识别更可能获得CCB长期良好反应的患者。
局限性
- 回顾性研究设计。
- 仅纳入特发性、遗传性或药物诱导性PAH中接受急性血管反应测试者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Among patients with pulmonary arterial hypertension (PAH), acute vasoreactivity testing during right heart catheterization may identify acute vasoresponders, for whom treatment with high-dose calcium channel blockers (CCBs) is recommended. However, long-term outcomes in the current era remain largely unknown. We sought to evaluate the implications of acute vasoreactivity response for long-term response to CCBs and other outcomes. METHODS: Patients diagnosed with PAH between January 1999 and December 2018 at 15 pulmonary hypertension centers were included and analyzed retrospectively. In accordance with current guidelines, acute vasoreactivity response was defined by a decrease of mean pulmonary artery pressure by ≥10 mm Hg to reach <40 mm Hg, without a decrease in cardiac output. Long-term response to CCBs was defined as alive with unchanged initial CCB therapy with or without other initial PAH therapy and World Health Organization functional class I/II and/or low European Society of Cardiology/European Respiratory Society risk status at 12 months after initiation of CCBs. Patients were followed for up to 5 years; clinical measures, outcome, and subsequent treatment patterns were captured. RESULTS: Of 3702 patients undergoing right heart catheterization for PAH diagnosis, 2051 had idiopathic, heritable, or drug-induced PAH, of whom 1904 (92.8%) underwent acute vasoreactivity testing. A total of 162 patients fulfilled acute vasoreactivity response criteria and received an initial CCB alone (n=123) or in combination with another PAH therapy (n=39). The median follow-up time was 60.0 months (interquartile range, 30.8-60.0), during which overall survival was 86.7%. At 12 months, 53.2% remained on CCB monotherapy, 14.7% on initial CCB plus another initial PAH therapy, and the remaining patients had the CCB withdrawn and/or PAH therapy added. CCB long-term response was found in 54.3% of patients. Five-year survival was 98.5% in long-term responders versus 73.0% in nonresponders. In addition to established vasodilator responder criteria, pulmonary artery compliance at acute vasoreactivity testing, low risk status and NT-proBNP (N-terminal pro-B-type natriuretic peptide) levels at early follow-up correlated with long-term response and predicted survival. CONCLUSIONS: Our data display heterogeneity within the group of vasoresponders, with a large subset failing to show a sustained satisfactory clinical response to CCBs. This highlights the necessity for comprehensive reassessment during early follow-up. The use of pulmonary artery compliance in addition to current measures may better identify those likely to have a good long-term response.
引用
- Gerhardt F, Fiessler E, Olsson KM, et al. Positive Vasoreactivity Testing in Pulmonary Arterial Hypertension: Therapeutic Consequences, Treatment Patterns, and Outcomes in the Modern Management Era. Circulation. 2024. PMID: 38606558. doi:10.1161/CIRCULATIONAHA.122.063821
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。